(H) T-L14 — Competitive Intelligence Brief

(H) T-L14 ((H) T-L14) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell therapy. Area: Oncology.

marketed T-cell therapy T-cells Oncology Small molecule

Target snapshot

(H) T-L14 ((H) T-L14) — National Taiwan University Hospital. T-L14 is a T-cell therapy that enhances anti-tumor immune response.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
(H) T-L14 TARGET	(H) T-L14	National Taiwan University Hospital	marketed	T-cell therapy	T-cells
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Tice Bcg	bcg	Pfizer	marketed	Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]	BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.
ROVALCYTE	ROVALCYTE	University Hospital, Rouen	phase 3	Autologous T-cell therapy
CTX001	CTX001	Vertex Pharmaceuticals Incorporated	phase 3	CAR-T cell therapy / Gene-edited T-cell therapy	BCMA (B-cell maturation antigen) / Tumor-associated antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell therapy class)

1. National Taiwan University Hospital · 1 drug in this class